{
    "nctId": "NCT02861859",
    "briefTitle": "Individualised Versus Standard Care for Breast Cancer Patients at High-risk for Chemotherapy-induced Nausea and Vomiting The ILIAD Study",
    "officialTitle": "A Randomized Trial of Individualised Care Versus Standard Care for Breast Cancer Patients at High Risk for Chemotherapy Induced Nausea and Vomiting. The ILIAD Study",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE3",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 221,
    "primaryOutcomeMeasure": "High personal risk of Chemotherapy-induced nausea and vomiting",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Newly diagnosed invasive breast cancer (stage I-III) scheduled to receive neo/adjuvant anthracycline/cyclophosphamide or platinum-based chemotherapy\n* \u226518 years\n* Able to provide consent and complete all study-related diaries and questionnaires.\n\nExclusion Criteria:\n\n* Received previous chemotherapy\n* Symptoms of nausea or vomiting at baseline\n* On chronic antiemetic therapy (e.g. metoclopramide); on daily long term oral steroids prior to chemotherapy\n* Allergic or having a medical condition that makes the administration of olanzapine, aprepitant, 5-HT3 antagonists or dexamethasone contraindicated\n* Uncontrolled diabetes\n* Known/documented medical/psychiatric illness that would interfere with patients' ability to complete the diary and study-related questionnaires.",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}